ACE2, a new regulator of the renin-angiotensin system

被引：258

作者：

Burrell, LM ^{[1
]}

Johnston, CI

Tikellis, C

Cooper, ME

机构：

[1] Univ Melbourne, Dept Med, Austin Hlth, Heidelberg Hts, Vic 3081, Australia

[2] Baker Heart Res Inst, Melbourne, Vic 8088, Australia

来源：

TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2004年 / 15卷 / 04期

关键词：

D O I：

10.1016/j.tem.2004.03.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Angiotensin-converting enzyme (ACE) is a zinc metalloproteinase and a key regulator of the renin-angiotensin system (RAS). ACE2 is a newly described enzyme identified in rodents and humans with a more restricted distribution than ACE, and is found mainly in heart and kidney. ACE2 cleaves a single residue from angiotensin I (Ang I) to generate Ang 1-9, and degrades Ang II, the main effector of the RAS, to the vasodilator Ang 1-7. The importance of ACE2 in normal physiology and pathophysiological states is largely unknown. ACE2 might act in a counter-regulatory manner to ACE, modulating the balance between vasoconstrictors and vasodilators within the heart and kidney, and playing a significant role in regulating cardiovascular and renal function.

引用

页码：166 / 169

页数：4

共 29 条

[1] Cardiac angiotensin-(1-7) in ischemic cardiomyopathy [J].

Averill, DB ;

Ishiyama, Y ;

Chappell, MC ;

Ferrario, CM .

CIRCULATION, 2003, 108 (17) :2141-2146

[2] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[3] Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction [J].

Chen, MM ;

Ashley, EA ;

Deng, DXF ;

Tsalenko, A ;

Deng, A ;

Tabibiazar, R ;

Ben-Dor, A ;

Fenster, B ;

Yang, E ;

King, JY ;

Fowler, M ;

Robbins, R ;

Johnson, FL ;

Bruhn, L ;

McDonagh, T ;

Dargie, H ;

Yakhini, Z ;

Tsao, PS ;

Quertermous, T .

CIRCULATION, 2003, 108 (12) :1432-1439

[4] Angiotensin-converting enzyme 2 is an essential regulator of heart function [J].

Crackower, MA ;

Sarao, R ;

Oudit, GY ;

Yagil, C ;

Kozieradzki, I ;

Scanga, SE ;

Oliveira-dos-Santos, AJ ;

da Costa, J ;

Zhang, LY ;

Pei, Y ;

Scholey, J ;

Ferrario, CM ;

Manoukian, AS ;

Chappell, MC ;

Backx, PH ;

Yagil, Y ;

Penninger, JM .

NATURE, 2002, 417 (6891) :822-828

[5] Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors [J].

Dales, NA ;

Gould, AE ;

Brown, JA ;

Calderwood, EF ;

Guan, B ;

Minor, CA ;

Gavin, JM ;

Hales, P ;

Kaushik, VK ;

Stewart, M ;

Tummino, PJ ;

Vickers, CS ;

Ocain, TD ;

Patane, MA .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (40) :11852-11853

[6] The secret life of ACE2 as a receptor for the SARS virus [J].

Dimitrov, DS .

CELL, 2003, 115 (06) :652-653

[7] A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 [J].

Donoghue, M ;

Hsieh, F ;

Baronas, E ;

Godbout, K ;

Gosselin, M ;

Stagliano, N ;

Donovan, M ;

Woolf, B ;

Robison, K ;

Jeyaseelan, R ;

Breitbart, RE ;

Acton, S .

CIRCULATION RESEARCH, 2000, 87 (05) :E1-E9

[8] Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins [J].

Donoghue, M ;

Wakimoto, H ;

Maguire, CT ;

Acton, S ;

Hales, P ;

Stagliano, N ;

Fairchild-Huntress, V ;

Xu, J ;

Lorenz, JN ;

Kadambi, V ;

Berul, CI ;

Breitbart, RE .

JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2003, 35 (09) :1043-1053

[9] Vasoactive potential of the B1 bradykinin receptor in normotension and hypertension [J].

Duka, I ;

Kintsurashvili, E ;

Gavras, I ;

Johns, C ;

Bresnahan, M ;

Gavras, H .

CIRCULATION RESEARCH, 2001, 88 (03) :275-281

[10] Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction [J].

Duncan, AM ;

Burrell, LM ;

Kladis, A ;

Campbell, DJ .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 28 (06) :746-754

← 1 2 3 →